Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide. The oral medication failed to pare back progression in the memory-loss disease. NVO has been on a steep, downward trajectory since topping out at a record high of $148.15 in June of 2024. The 120-day moving average has loomed as overhead resistance, capping several breakout attempts this past year ...

News of the first successful drug trial in the deadly neurodegenerative disorder Huntington’s is spreading quickly through a cluster of potential patients in northern Scotland. Bloomberg's Prognosis explains why.... https://t.co/2Dop2iAzYt ...